BioCentury | Mar 31, 2017
Financial News

Antiva Biosciences completes venture financing

...On March 28, HPV play Antiva Biosciences Inc. (Menlo Park, Calif.) raised $22 million in a series C...
...and existing investors Canaan Partners and Sofinnova Ventures also participated. Antiva Biosciences Inc. , Menlo Park, Calif. Alicia Parker Antiva Biosciences Inc....
BioCentury | Mar 28, 2017
Financial News

Antiva raises $22M series C round

...program or seek additional venture capital. Brace President and CEO Vinzenz Ploerer joined Antiva's board. Becky Simon HTI-1968 Antiva Biosciences Inc....
BioCentury | Aug 10, 2015
Financial News

Antiva Biosciences completes venture financing

Antiva Biosciences Inc. , San Diego, Calif. Business: Infectious Date completed: 2015-08-06 Type: Venture financing Raised: $16 million Investors: Canaan Partners; Sofinnova Ventures; existing investors WIR Staff Infectious...
BioCentury | Aug 7, 2015
Financial News

Antiva raises $16M in series B

...Wende Hutton and Sofinnova's David Kabakoff will join Antiva's board. Antiva was formerly known as Hera Therapeutics...
BioCentury | Sep 22, 2014
Clinical News

Hera Therapeutics preclinical data

...were presented at the International Papillomavirus Conference in Seattle. HTI-1968 is a topical direct-acting antiviral. Hera Therapeutics...
Items per page:
1 - 5 of 5
BioCentury | Mar 31, 2017
Financial News

Antiva Biosciences completes venture financing

...On March 28, HPV play Antiva Biosciences Inc. (Menlo Park, Calif.) raised $22 million in a series C...
...and existing investors Canaan Partners and Sofinnova Ventures also participated. Antiva Biosciences Inc. , Menlo Park, Calif. Alicia Parker Antiva Biosciences Inc....
BioCentury | Mar 28, 2017
Financial News

Antiva raises $22M series C round

...program or seek additional venture capital. Brace President and CEO Vinzenz Ploerer joined Antiva's board. Becky Simon HTI-1968 Antiva Biosciences Inc....
BioCentury | Aug 10, 2015
Financial News

Antiva Biosciences completes venture financing

Antiva Biosciences Inc. , San Diego, Calif. Business: Infectious Date completed: 2015-08-06 Type: Venture financing Raised: $16 million Investors: Canaan Partners; Sofinnova Ventures; existing investors WIR Staff Infectious...
BioCentury | Aug 7, 2015
Financial News

Antiva raises $16M in series B

...Wende Hutton and Sofinnova's David Kabakoff will join Antiva's board. Antiva was formerly known as Hera Therapeutics...
BioCentury | Sep 22, 2014
Clinical News

Hera Therapeutics preclinical data

...were presented at the International Papillomavirus Conference in Seattle. HTI-1968 is a topical direct-acting antiviral. Hera Therapeutics...
Items per page:
1 - 5 of 5